Walgreens is taking colorectal cancer screening out of the clinic and into retail—partnering with Exact Sciences to offer Cologuard access directly through its nationwide pharmacy footprint.
At first glance, this looks like a convenience play. But the deeper shift is structural: screening is being embedded into everyday healthcare touchpoints, targeting the persistent gap where over one-third of eligible adults remain unscreened.
By integrating clinical workflows into pharmacy operations, Walgreens is turning pharmacists into activation points for preventive care—bridging awareness and action in a way traditional healthcare settings often fail to do.
The model also reflects a broader trend: decentralizing screening from specialist-led environments to scalable, consumer-facing platforms. Non-invasive tests like Cologuard lower the barrier to entry—but also raise an important strategic question for GI:
👉 As access expands outside the clinic, who owns the screening journey—and who captures the downstream value?
In the push to improve early detection, pharmacies may not just increase screening rates—they may quietly redefine how patients enter the colorectal care pathway.